Nasopharyngeal carcinoma (NPC) is a head and neck malignant tumor rare throughout most of the world but common in Southeast Asia, especially in Southern China. The phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 promotes cellular proliferation, survival, malignant transformation and metastasis. However, whether the alterations of the expression of p-eIF4E and p-Mnk1 protein are associated with clinicopathologic/prognostic implication for NPC has not been reported. The purposes of the present study are to examine the expression of p-eIF4E and p-Mnk1 protein in NPC and non-cancerous nasopharyngeal epithelial tissues by immunohistochemistry and evaluate the association between the expression of p-eIF4E and p-Mnk1 protein and clinicopathological characteristics of NPC. The results showed that the positive percentage of p-Mnk1 and p-eIF4E proteins expression in NPC (83.5% and 75.4%, respectively) was significantly higher than that in non-cancerous nasopharyngeal epithelium (40.0% and 32.9%, respectively). The positive expression of p-eIF4E and p-Mnk1 in the NPC with cervical lymph node metastasis was significantly higher than those without lymph node metastasis. Additionally, p-eIF4E expression was more pronouncedly increased in metastatic NPC than the matched primary NPC. Increase of p-eIF4E and p-Mnk1 expression was significantly correlated inversely with overall survival. Spearman’s rank correlation test further showed that expression of p-Mnk1 was strongly positive correlated with expression of p-eIF4E in NPC. The expression of p-Mnk1 and p-eIF4E in NPC was proved to be the independent prognostic factors regardless of lymph node metastasis, clinical stages and combination of radiotherapy and chemotherapy, histological type, age and gender by multivariate analysis. Taken together, high expression of p-Mnk1 and p-eIF4E might be novel valuable biomarkers to predict poor prognosis of NPC and therapeutic targets for developing the valid treatment strategies.
References
[1]
Cho WC (2007) Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 6: 1.
[2]
Chou J, Lin YC, Kim J, You L, Xu Z, et al. (2008) Nasopharyngeal carcinoma–review of the molecular mechanisms of tumorigenesis. Head Neck 30: 946–963. doi: 10.1002/hed.20833
[3]
Sham JST, Choy D, Wei WI (1990) Nasopharyngeal carcinoma: orderly neck node spread. Int J Radiat Oncol Biol Phys 19: 929–933. doi: 10.1016/0360-3016(90)90014-b
[4]
Pan CC, Lu J, Yu JR, Chen P, Li W, et al. (2012) Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp Ther Med 4: 334–338. doi: 10.3892/etm.2012.584
[5]
Razak AR, Siu LL, Liu FF, Ito E, O’Sullivan B, et al. (2010) Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 46: 1967–1978. doi: 10.1016/j.ejca.2010.04.004
[6]
Tao Q, Chan AT (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 4 9: 1–24. doi: 10.1017/s1462399411001864
[7]
Wei WI, Kwong DL (2010) Current management strategy of nasopharyngeal carcinoma. Clin Exp Otorhinolaryngol 3: 1–12. doi: 10.3342/ceo.2010.3.1.1
[8]
Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477–480. doi: 10.1038/nature03205
[9]
Zimmer SG, DeBenedetti A, Graff JR (2000) Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20: 1343–1351.
[10]
Waskiewicz AJ, Flynn A, Proud CG, Cooper JA (1997) Mitogenactivated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16: 1909–1920. doi: 10.1093/emboj/16.8.1909
[11]
Clemens MJ, Bommer UA (1999) Translational control: the cancer connection. The international journal of biochemistry & cell biology 31: 1–23. doi: 10.1016/s1357-2725(98)00127-7
[12]
Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, et al. (2004) eIF4E–from translation to transformation. Oncogene 23: 3172–3179. doi: 10.1038/sj.onc.1207549
[13]
Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232–3237. doi: 10.1101/gad.1604407
[14]
Khoury T, Alrawi S, Ramnath N, Li Q, Grimm M, et al. (2009) Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 10: 58–66. doi: 10.3816/clc.2009.n.009
[15]
Nathan CO, Franklin S, Abreo FW, Nassar R, de Benedetti A, et al. (1999) Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope. 109: 1253–1258. doi: 10.1097/00005537-199908000-00013
[16]
Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, et al. (1999) Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene. 1999 18(15): 2507–2517. doi: 10.1038/sj.onc.1202563
[17]
Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, et al. (1999) Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin’s lymphomas. The American journal of pathology 155: 247–255. doi: 10.1016/s0002-9440(10)65118-8
[18]
Rosenwald IB, Pechet L, Han A, Lu L, Pihan G, et al. (2001) Expression of translation initiation factors elF-4E and elF-2alpha and a potential physiologic role of continuous protein synthesis in human platelets. Thromb Haemost 85: 142–151.
[19]
Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, et al. (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69: 3866–3873. doi: 10.1158/0008-5472.can-08-3472
[20]
De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189–3199. doi: 10.1038/sj.onc.1207545
[21]
Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539–6549. doi: 10.1128/mcb.24.15.6539-6549.2004
[22]
Mahalingam M, Cooper JA (2001) Phosphorylation of mammalian eIF4E by Mnk1 and Mnk2: tantalizing prospects for a role in translation. Prog Mol Subcell Biol 27: 132–142. doi: 10.1007/978-3-662-09889-9_5
[23]
Pyronnet S (2000) Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 60: 1237–1243. doi: 10.1016/s0006-2952(00)00429-9
[24]
Muta D, Makino K, Nakamura H, Yano S, Kudo M, et al. (2011) Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 101: 33–39. doi: 10.1007/s11060-010-0233-6
[25]
Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16: 240–248. doi: 10.1158/1078-0432.ccr-09-0986
[26]
Wheater MJ, Johnson PW, Blaydes JP (2010) The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 10: 728–735. doi: 10.4161/cbt.10.7.12965
[27]
Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, et al. (2011) Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71: 1849–1857. doi: 10.1158/0008-5472.can-10-3298
[28]
Ferrandiz-Pulido C, Masferrer E, Toll A, Hernandez-Losa J, Mojal S, et al. (2013) mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E overexpression correlate with aggressive tumoral behavior. J Urol. 190: 2288–2295. doi: 10.1016/j.juro.2013.06.015
[29]
Liang S, Guo R, Zhang Z, Liu D, Xu H, et al. (2013) Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol Rep 29: 2422–2430. doi: 10.3892/or.2013.2397
[30]
Pons B, Peg V, Vázquez-Sánchez MA, López-Vicente L, Argelaguet E, Coch L, et al. (2011) The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. Int J Oncol 39: 1337–1345.
[31]
Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, et al. (2009) Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 8: 1463–1469. doi: 10.4161/cbt.8.15.8960
[32]
Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, et al. (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 22: 2279–2288. doi: 10.1093/carcin/bgn221
[33]
Wu M, Liu Y, Di X, Kang H, Zeng H, et al. (2013) EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma. Med Oncol 30: 400 doi: 10.1007/s12032-012-0400-z.
[34]
Hou J, Lam F, Proud C, Wang S (2012) Targeting Mnks for cancer therapy. Oncotarget 3: 118–131.
[35]
Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, et al. (2012) MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 31: 4434–4446. doi: 10.1038/onc.2011.617
[36]
Lee CC, Chu ST, Chou P, Lee CC, Chen LF (2008) The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma. Clin Otolaryngol 33: 442–449. doi: 10.1111/j.1749-4486.2008.01770.x
[37]
Segrelles C, Ruiz S, Santos M, Martínez-Palacio J, Lara MF, et L (2004) Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis 25: 1137–1147. doi: 10.1093/carcin/bgh132
[38]
Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107: 14134–14139. doi: 10.1073/pnas.1005320107
[39]
Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, et al. (2003) Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 129: 794–799. doi: 10.1001/archotol.129.7.794
